Shamburg News · 8-K filed Oct 14, 2026, 5:11 PM EDT

Rezolute Completes Enrollment in Phase 3 upLIFT Study of Ersodetug; Topline Data Expected Mid-December 2026

RZLT · Rezolute, Inc.

  • Other event
  • Reg FD disclosure
  • Materiality: medium

Rezolute, Inc. announced on October 14, 2026 that the open-label Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism is fully enrolled. The Company expects topline data in mid-December 2026 and plans to continue its expanded access program. The filing was furnished under Item 7.01 (Regulation FD) with the press release as Exhibit 99.1.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001104659-26-115874.

Written from the filing by Shamburg Markets. Figures are as reported by the company.